FIELD: medicine.
SUBSTANCE: invention refers to medicine, namely to rheumatology and can be used for optimizing treatment of patients with early forms of psoriatic arthritis (PsA). According to the developed method, the following complex of parameters is determined in 3 months after the beginning of treatment by the basic anti-inflammatory preparations: DAPSA index, FACIT fatigue, patient's body weight index, Westergren's ESR, number of inflamed enthesis and patient's sex. Based on the obtained data, an original formula is used to calculate an index indicating the need to transfer the PsA patient to the therapy with genetically engineered biological preparations.
EFFECT: created method allows to determine indications for beginning of reception of genetic engineering biological preparations with ineffectiveness of basic anti-inflammatory preparations in early forms of psoriatic arthritis.
1 cl
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD FOR DETERMINING PSORIATIC ARTHRITIS ACTIVITY | 2020 |
|
RU2746884C1 |
| METHOD OF PREDICTING ACHIEVEMENT OF MINIMAL DISEASE ACTIVITY DURING THERAPY IN TREATMENT OF PATIENTS WITH PSORIATIC ARTHRITIS | 2022 |
|
RU2808550C1 |
| METHOD FOR ASSESSING THE RISK OF JOINT EROSIONS IN PATIENTS WITH PSORIATIC ARTHRITIS | 2022 |
|
RU2791661C1 |
| METHOD FOR RAPID ASSESSMENT OF AXIAL SKELETON INVOLVEMENT RISK IN EARLY FORMS OF PSORIATIC ARTHRITIS | 2020 |
|
RU2724276C1 |
| METHOD FOR PREDICTING THE COURSE OF PSORIATIC ARTHRITIS | 2021 |
|
RU2765111C1 |
| METHOD FOR ASSESSING THE EFFECTIVENESS OF TREATMENT OF PSORIATIC ARTHRITIS USING OXIDATIVE STRESS PARAMETERS | 2021 |
|
RU2762104C1 |
| METHOD FOR ASSESSING THE EFFECTIVENESS OF TREATMENT OF PSORIATIC ARTHRITIS USING ANTIOXIDANT SYSTEM PARAMETERS | 2021 |
|
RU2762105C1 |
| METHOD FOR DETERMINING CLINICALLY SIGNIFICANT FATIGUE IN A PATIENT WITH RHEUMATOID ARTHRITIS AGAINST THE BACKGROUND OF 5-YEAR THERAPY WITH BASIC ANTI-INFLAMMATORY DRUGS OR BASIC ANTI-INFLAMMATORY DRUGS IN COMBINATION WITH GENETICALLY ENGINEERED BIOLOGICAL DRUGS AND/OR PSYCHOPHARMACOTHERAPY AND CONCOMITANT ANXIETY-DEPRESSIVE SPECTRUM DISORDER | 2021 |
|
RU2760220C1 |
| METHOD FOR PSORIATIC ARTHRITIS DIAGNOSTICS | 2016 |
|
RU2629627C1 |
| METHOD FOR DETERMINING REMITTANCE IN A PATIENT SUFFERING RHEUMATOID ARTHRITIS WITH UNDERLYING 5-YEAR THERAPY OF BASIC ANTI-INFLAMMATORY PREPARATIONS OR BASIC ANTI-INFLAMMATORY PREPARATIONS IN COMBINATION WITH GENETICALLY ENGINEERED BIOLOGICAL PREPARATIONS AND ACCOMPANYING COMORBID ANXIETY-DEPRESSIVE DISORDER | 2019 |
|
RU2701638C1 |
